摘要
目的观察重组人前尿激酶(rhPro-UK)对心肌梗死患者纤溶系统的影响,建立纤溶指标的临床参考标准。方法将127例符合溶栓标准的急性心肌梗死患者随机给予不同剂量的rhPro-UK进行溶栓。观察溶栓前和溶栓后2h血浆纤溶酶原(PLG)、抗纤溶酶(α2-AP)和纤溶酶原激活物抑制物(PAI)的变化以及出血并发症。结果各用药组溶栓开始后2h的PLG及α2-AP活性较溶栓前显著降低(P<0.001),rhPro-Uk组与UK组相比溶栓前后未见显著性差异。结论动态监测心机梗死患者rhPro-UK溶栓后血浆中PLG、AP和PAI有助于疗效判定和调节药物剂量。
Aim To set up the clinical criteria for thrombolytic therapy by conducting thrombosis tests on myocardial infarction patients receiving Pro-Urokinase. Methods rhPro-UK at different dose was assigned to 127 acute myocardial infarction patients randomly. Plasminogen, α2-antiplasmin and plasminogen activator inhibitor（PAI） were determined before and 2 hours after thrombolysis. Results The activity of PLG and α2- AP of each group decreased the significantly 2 hours after therapy （ P 〈 0. 001 ）. No significant difference in α2-AP and PLG was found between the rhPro-UK and UK group before after thrombolysis. Conclusion With pro-urckinase used, plasma PLG, α2-AP and PAI tests can help evaluate the primary efficacy end points and guide dosage of thrombolysis.
出处
《解放军药学学报》
CAS
2006年第6期422-424,共3页
Pharmaceutical Journal of Chinese People's Liberation Army
